慢性阻塞性肺疾病患者非破裂性胸主动脉瘤腔内修复术的30天结局
本研究利用美国外科医师学会国家手术质量改进计划数据库2005至2022年数据,比较慢性阻塞性肺疾病(COPD)与非COPD患者因非破裂性胸主动脉瘤行胸主动脉腔内修复术(TEVAR)的30天结局。经1:1倾向性评分匹配后,COPD组与非COPD组30天死亡率分别为5.7%与4.8%(p=0.58),无显著差异,其他30天结局亦相当。
要点
- COPD患者占TEVAR人群20.2%,合并症负担更高。
- 匹配后COPD组与非COPD组30天死亡率5.7% vs 4.8%(p=0.58)。
- COPD与非COPD患者所有其他30天结局相当。
核心结论
- COPD可能通过共享病理生理通路与胸主动脉瘤发生相关,但COPD似乎与TEVAR术后主要不良30天结局无关。
- 未来研究应探索接受TEVAR的COPD患者的长期结局。
研究设计与样本
- 利用美国外科医师学会国家手术质量改进计划数据库2005至2022年数据,纳入因非破裂性胸主动脉瘤行TEVAR的患者。
- 采用1:1倾向性评分匹配 demographics、术前特征和麻醉方式,比较COPD与非COPD患者。
- 共525例(20.2%)COPD患者和2071例(79.8%)非COPD患者。
主要发现
- COPD在胸主动脉瘤患者中的患病率显著高于一般人群,且COPD患者合并症负担更高。
- 倾向性评分匹配后,COPD组与非COPD组30天死亡率分别为5.7%与4.8%(p=0.58),无显著差异。
- COPD患者所有其他30天结局与非COPD患者相当。
关键数值与推荐
- 倾向性评分匹配后COPD组30天死亡率为5.7%,非COPD组为4.8%(p=0.58)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracic Endovascular Aortic Repair (TEVAR) is the preferred treatment for thoracic aneurysms for eligible patients. Chronic obstructive pulmonary disease (COPD) is a common comorbidity that shares common inflammatory pathways with atherosclerosis, the major cause of thoracic aneurysms. However, surgical outcomes of TEVAR among patients with COPD have not been thoroughly investigated. This study aimed to assess the 30-day postoperative outcomes for COPD patients who have undergone TEVAR for non-ruptured thoracic aortic aneurysms, using data from a multi-institutional national registry. METHODS: Patients who underwent TEVAR for non-ruptured thoracic aneurysms were identified in the American College of Surgeons National Surgical Quality Improvement Program database from 2005 to 2022. A 1:1 propensity-score matching was used to match demographics, preoperative characteristics, and anesthesia between COPD and non-COPD patients. Thirty-day mortality and other postoperative outcomes were compared. RESULTS: There were 525 (20.2%) COPD and 2,071 (79.8%) non-COPD patients who underwent TEVAR for the non-ruptured thoracic aneurysm. COPD was significantly more prevalent among patients with thoracic aneurysms compared to its incidence in the general population, and COPD patients also exhibited a higher burden of comorbidities. After 1:1 propensity-score matching, COPD and non-COPD patients had comparable 30-day mortality (5.7% vs 4.8%, p = 0.58). All other 30-day outcomes were comparable in COPD patients. CONCLUSION: While COPD might be linked to the development of thoracic aneurysms through potentially shared pathophysiological pathways, COPD does not appear to be related to major adverse 30-day outcomes in TEVAR. Future studies should aim to explore the long-term outcomes in COPD patients undergoing TEVAR.Clinical ImpactCOPD was significantly more prevalent among patients with thoracic aneurysms compared to the general population, and COPD patients also exhibited a higher burden of comorbidities. However, after propensity-score matching, COPD patients demonstrated comparable risks across all 30-day outcomes. Therefore, while COPD might be linked to the development of thoracic aneurysms through potentially shared pathophysiological pathways, COPD does not appear to be related to major adverse 30-day outcomes in TEVAR.
引用
- Li R, Sidawy A, Nguyen BN, et al. Thirty-Day Outcomes of Endovascular Repair of Non-Ruptured Thoracic Aneurysms in Patients with Chronic Obstructive Pulmonary Disease. J Endovasc Ther. 2025. PMID: 40252000. doi:10.1177/15266028251331776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。